Deep Lymph Node Biopsy

Background and indications

Image-guided percutaneous deep lymph node biopsy enables histological diagnosis of adenopathies not accessible to clinical palpation or simple surgical biopsy. Typical locations include retroperitoneal, mediastinal, pelvic, and mesenteric lymph nodes.

Main indications include: lymphoma diagnosis, solid cancer staging, characterization of adenopathies of undetermined origin (infectious, inflammatory, neoplastic), and obtaining material for molecular or immunohistochemical analysis.

Pre-procedure assessment

Assessment includes recent imaging (CT or MRI) identifying the target node and puncture trajectory, coagulation panel, and multidisciplinary discussion. The most accessible and representative node is selected.

Procedure

Under local anesthesia and light sedation, a biopsy needle (16-18G) is inserted under CT guidance (or ultrasound if accessible). 3 to 5 cores are obtained. For lymphoma diagnosis, sufficient sampling is essential as nodal architecture must be evaluated. The procedure takes 20 to 40 minutes.

Results and scientific evidence

Percutaneous core needle biopsy of deep lymph nodes offers 85-95% diagnostic yield and allows lymphoma subtyping in 80-90% of cases, sufficient to guide treatment in the vast majority of situations. It avoids diagnostic surgery in over 80% of cases.

Risks and complications

Complications are rare: local pain (5-10%), hematoma (< 3%), infection (< 0.5%). Risk varies by location (retroperitoneal vs superficial). Major complications are exceptional.

Recovery

Monitoring for 2-4 hours. Relative rest for 24 hours. Results within 5-10 days, potentially requiring complementary techniques (immunohistochemistry, flow cytometry).

Practical information

The procedure is performed as an outpatient or short inpatient stay depending on the case. It is performed by an interventional radiologist, in coordination with the hematologist or oncologist.